Seeking Alpha

Vical (VICL) +14% premarket after announcing Bristol-Myers Squibb (BMY) has licensed its...

Vical (VICL) +14% premarket after announcing Bristol-Myers Squibb (BMY) has licensed its patented platform DNA immunization technology to generate antibodies with potential therapeutic uses in humans on a non-exclusive, worldwide basis. Financial terms of the agreement were not disclosed.
Comments (1)
  • AppleGrand
    , contributor
    Comments (17) | Send Message
     
    why is this kept a secret from shareholders?
    14 Sep 2012, 04:26 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|